IRIS Archives

Information and Referral and Internet Sightings

IRIS@LISTSERV.ICORS.ORG
Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
web: lucrative $15 billion antidepressant market
From:
Sylvia Caras <[log in to unmask]>
Reply To:
[log in to unmask]
Date:
Mon, 2 Jun 2008 09:45:24 -0700
Content-Type:
text/plain
Parts/Attachments:
text/plain (15 lines) 
IntelGenx Announces Positive Results From First Pilot Pharmacokinetic 
Study on Anti-Depressant CPI-300
 From Marketwire Canada (English) - May 29, 2008
SAINT LAURENT, QUEBEC--(Marketwire - May 29, 2008) - IntelGenx Corp. 
today announced that the pilot clinical trial of the antidepressant 
CPI-300 shows strong positive results. The preliminary results of the 
fasted and fed studies show that CPI-300 is equivalent to the reference 
product.  The product uses IntelGenx's proprietary Versatab oral 
delivery technology and will address the largest market within the 
company's current pipeline; the lucrative $15 billion antidepressant 
market. IntelGenx is on track with its development timeline and project 
commercialization by the second half of 2009.

www.peoplewho.org

ATOM RSS1 RSS2